About: Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness
Creator	Lee, Byung-Wan Rhee, Eun-Jung Kim, Jae Kim, So Cho, Young Jin, Heung Lee, Yong-Ho
Source	Medline; PMC
abstract	Despite the rapidly increasing prevalence of non-alcoholic fatty liver disease (NAFLD) in type 2 diabetes (T2D), few treatment modalities are currently available. We investigated the hepatic effects of the novel thiazolidinedione (TZDs), lobeglitazone (Duvie) in T2D patients with NAFLD. We recruited drug-naïve or metformin-treated T2D patients with NAFLD to conduct a multicenter, prospective, open-label, exploratory clinical trial. Transient liver elastography (Fibroscan(®); Echosens, Paris, France) with controlled attenuation parameter (CAP) was used to non-invasively quantify hepatic fat contents. Fifty patients with CAP values above 250 dB/m were treated once daily with 0.5 mg lobeglitazone for 24 weeks. The primary endpoint was a decline in CAP values, and secondary endpoints included changes in components of glycemic, lipid, and liver profiles. Lobeglitazone-treated patients showed significantly decreased CAP values (313.4 dB/m at baseline vs. 297.8 dB/m at 24 weeks; P = 0.016), regardless of glycemic control. Lobeglitazone improved HbA(1C) values (7.41% [57.5 mM] vs. 6.56% [48.2 mM]; P < 0.001), as well as the lipid and liver profiles of the treated patients. Moreover, multivariable linear regression analysis showed that hepatic fat reduction by lobeglitazone was independently associated with baseline values of CAP, liver stiffness, and liver enzymes, and metformin use. Lobeglitazone treatment reduced intrahepatic fat content, as assessed by transient liver elastography, and improved glycemic, liver, and lipid profiles in T2D patients with NAFLD. Further randomized controlled trials using liver histology as an end point are necessary to evaluate the efficacy of lobeglitazone for NAFLD treatment (Clinical trial No. NCT02285205).
has issue date	2016-11-08(xsd:dateTime)
bibo:doi	10.3346/jkms.2017.32.1.60
bibo:pmid	27914133
has license	cc-by-nc
sha1sum (hex)	b66704a03a688c4065abff41c4977c4c9939c230
schema:url	https://doi.org/10.3346/jkms.2017.32.1.60
resource representing a document's title	Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness
has PubMed Central identifier	PMC5143300
has PubMed identifier	27914133
schema:publication	J Korean Med Sci
resource representing a document's body	covid:b66704a03a688c4065abff41c4977c4c9939c230#body_text
is schema:about of	named entity 'PREVALENCE' named entity '28313' named entity '2 MM' named entity 'EFFICACY' named entity 'NAFLD' named entity 'INCLUDED' named entity 'NON-ALCOHOLIC FATTY LIVER DISEASE' named entity 'TYPE 2 DIABETES' named entity 'PROSPECTIVE' named entity 'VALUES' named entity 'CHANGES' named entity 'TRANSIENT' named entity 'REGARDLESS' named entity 'NOVEL' named entity 'INVESTIGATED' named entity 'LIVER HISTOLOGY' named entity 'SECONDARY' named entity 'ASSOCIATED WITH' named entity 'PATIENTS' named entity 'INTRAHEPATIC' named entity 'ONCE DAILY' named entity 'ELASTOGRAPHY' named entity 'GLYCEMIC' named entity 'ASSESSED' named entity 'IMPROVED' named entity '250' named entity '24 WEEKS' named entity 'THIAZOLIDINEDIONE' named entity 'EFFECTS' named entity '0.5' named entity 'LIVER' named entity 'values' named entity 'values' named entity 'patients' named entity 'randomized controlled trials' named entity 'non-alcoholic fatty liver disease' named entity 'ALCOHOLIC FATTY LIVER DISEASE' named entity 'EFFICACY' named entity 'LIVER ENZYMES' named entity 'RANDOMIZED CONTROLLED TRIALS' named entity '0.001' named entity 'LIVER STIFFNESS' named entity 'DECREASED' named entity 'FAT' named entity 'HBA1C' named entity 'TYPE 2 DIABETES' named entity 'CURRENTLY' named entity 'RAPIDLY' named entity 'USED' named entity 'HEPATIC' named entity 'METFORMIN' named entity 'NON-' named entity 'NOVEL' named entity 'LOBEGLITAZONE' named entity 'RELATED' named entity 'THIAZOLIDINEDIONE' named entity 'IMPROVES' named entity 'ITS' named entity 'RESPONSIVENESS' named entity 'USING' named entity 'GLYCEMIC CONTROL' named entity 'TREATMENT' named entity 'FIFTY' named entity 'DRUG' named entity 'AVAILABLE' named entity 'DECLINE' named entity 'USE' named entity 'QUANTIFY' named entity 'INCREASING' named entity 'OPEN' named entity 'LINEAR REGRESSION ANALYSIS' named entity '016' named entity 'T2D' named entity 'REDUCED' named entity 'LOBEGLITAZONE'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software